Squarepoint’s Argos Therapeutics, Inc. ARGS Stock Holding History

Squarepoint’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-715	Closed	-$5K	–	2074
2017 Q2	$5K	Buy	+715	New	+$6.09K	﹤0.01%	1495

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

KeyBank National Association Cleveland, Ohio $27.4B AUM 24.17% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Squarepoint's ARGS Position: Q3 2017 in Review

Squarepoint sold out of Argos Therapeutics, Inc. (ARGS) in Q3 2017, closing a stake of 715 shares — an estimated $5K sold.

Squarepoint first reported a position in ARGS in Q2 2017 and held it in 1 quarter. The position peaked at $5K in Q2 2017. 29 funds tracked by Wall St. Rank hold ARGS as of Q3 2017.

Squarepoint reported no remaining Argos Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
Squarepoint sold 715 Argos Therapeutics, Inc. shares in Q3 2017, an estimated $5K.
Squarepoint first reported a position in Argos Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
Squarepoint's Argos Therapeutics, Inc. position peaked at $5K in Q2 2017.
29 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q3 2017.

Based on Squarepoint's 13F filing for Q3 2017, filed 14 Nov 2017.